Marshall Wace
GLMD icon

Marshall Wace’s Galmed Pharmaceuticals GLMD Stock Holding History

Marshall Wace’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-127
Closed -$109K – 1837
2019
Q3 		$109K Buy
+127
New +$127K ﹤0.01% 1385

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Marshall Wace's GLMD Position: Q4 2019 in Review

Marshall Wace sold out of Galmed Pharmaceuticals (GLMD) in Q4 2019, closing a stake of 127 shares — an estimated $109K sold.

Marshall Wace first reported a position in GLMD in Q3 2019 and held it in 1 quarter. The position peaked at $109K in Q3 2019. 31 funds tracked by Wall St. Rank hold GLMD as of Q4 2019.

  • Marshall Wace reported no remaining Galmed Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace sold 127 Galmed Pharmaceuticals shares in Q4 2019, an estimated $109K.
  • Marshall Wace first reported a position in Galmed Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Marshall Wace's Galmed Pharmaceuticals position peaked at $109K in Q3 2019.
  • 31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2019.

Based on Marshall Wace's 13F filing for Q4 2019, filed 14 Feb 2020.